Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7815601 | 0.81 | KMT2A (0.52) | GAACA9CA2THRBKMT2A | |
| SCHEMBL8344573 | 0.77 | CA2 (0.54) | GAACA9CA2KMT2AMEN1 | |
| SCHEMBL16278731 | 0.77 | GAA (0.39) | GAACA9CA2THRBKMT2A | |
| SCHEMBL10670393 | 0.77 | GAA (0.53) | GAACA9CA2THRBKMT2A | |
| SCHEMBL16278118 | 0.75 | CA2 (0.53) | GAACA9CA2KMT2AMEN1 | |
| SCHEMBL375941 | 0.75 | CA2 (0.53) | GAACA9CA2CA12CA1 | |
| SCHEMBL7952457 | 0.75 | CA12 (0.53) | CA9CA2THRBCA12CA1 | |
| SCHEMBL5937341 | 0.73 | GAA (0.43) | GAACA9CA2KMT2AMEN1 | |
| SCHEMBL6245339 | 0.73 | PLCG1 (0.50) | GAACA9CA2THRBKMT2A | |
| SCHEMBL10672364 | 0.73 | THRB (0.70) | GAACA9CA2THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844342-B2 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-20040067997-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | YU KUO-LONG (US) | 2004-04-08 | — | — | US | disclosed |
| US-20020099208-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-25 | — | — | US | disclosed |
| EP-0268990-A2 | New benzothiadiazine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099208-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | GAA 1087/4885CA9 3207/4885CA2 3532/4885 |
| US-20040067997-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | GAA 1087/4885CA9 3207/4885CA2 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.